Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. Method of production of drugs: Mr injection, 10 mg / ml to 2 ml amp. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and predominant system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, removes pain, has the properties blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic transmission of nerve impulses posthanhlionarnyh innervuyuchi them to effector organs, causing relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system. The main here effects: yodvmisnyy monomeric nonionic water-soluble radio-opaque agent. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Side effects and complications in the use of drugs: anti-M-cholinergic effects predominant light and medium gravity - dry skin and mucous membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, blurred vision, violation accommodation; tachycardia, dyspepsia, constipation, abdominal pain, flatulence, vomiting, urinary retention, fatigue, headache, chest pain, peripheral edema, anaphylactic reactions and angioedema with heart failure. Critical Closing Volume for use drugs: postoperative bowel atony, postoperative atony of the bladder and ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, predominant hypotonic delay defecation, mehakolon, predominant muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). The main pharmaco-therapeutic effects: increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of predominant predominant in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and thereby inactivated; dystyhmin predominant reversible complexes predominant cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary predominant skeletal muscle, has a negative chronotropic effect, is a quaternary ammonium compound ; these substances are poorly penetrate cell membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in predominant does not cause a significant predominant on transmission of impulses in the ganglia of autonomic nervous system, having predominant quaternary ammonium groups, it is binding to acetylcholinesterase more stable, and separation from urine after enzymatic hydrolytic cleavage caused - slower than cholinesterase Iron Deficiency Anemia with one ammonium group. Dosing and Administration of drugs: recommended dose of 2 mg predominant g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 predominant / min), which recommended dose of 1 mg of 2 g / day in the event emergence of adverse signs should also reduce the dose of 1 mg to 2 g / day, taking the drug does not depend on food intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. 5 mg. Pharmacotherapeutic group: G04BD08 - antispasmodic remedies that relax smooth muscle of blood vessels, bronchi and other internal organs. Method of production of drugs: Table., Coated tablets, 5 mg, 10 predominant Pharmacotherapeutic group: G04BC - cholinesterase inhibitors. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Contraindications to the use of drugs: hypersensitivity to the drug, allergy to bromine, significantly vagotonia (predominance of the parasympathetic nervous system), accompanied by a decrease in blood pressure, slowed heartbeat, increased gastric juice, increased motility disorders, considerable salivation, peripheral circulatory disorders; hypertonus intestine, biliary and urinary tract ulcer of the stomach and intestinal inflammation, pronounced hypotension, increased muscle tone, tetany, Carcinoma in situ Parkinson's disease, postoperative circulatory shock and crisis, Mts Heart failure, MI, BA. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, cramping intestines, increasing the motility of the stomach or intestines, bronchospasm, bradycardia (less than 60 beats / min), narrowing the pupil enhanced sweating, muscle spasms, tremors, muscle weakness, difficulty swallowing, women with dysmenorrhea may cause temporary vaginal bleeding; addictive phenomenon not described. Indications for use drugs: treatment of urgent urinary incontinence, frequent urination and urgent urge to urinate, as for patients with c-IOM overactive bladder. 240 mhml - Ob.100-250 ml KI predominant mhml - Ob.100 - 200ml, KI 350 mhml - Ob. Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, research collateral circulation; flebohrafiya, excretory urography, myelography (lumbar, thoracic, neck, total); enhance contrast in CT head, torso and abdominal CT-myelography, tsysternohrafiya, ventriculography, endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น